Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  

The Ohio Clinical Trial Collaborative (OCTC)

The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.

The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.

Review the OCTC working website at: http://ohioclintrials.org.

Contact Joe Peter at 216-702-5314 for more information.

 

Foundation Fighting Blindness and Harrington Discovery Institute

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.

• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.

For more information about Foundation Fighting Blindness visit the Fighting Blindness website.

 
National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH)

The NIH Office of Research on Women's Health (ORWH) and participating NIH components, including the National Institute on Drug Abuse, invite institutional career development award applications for Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Career Development Programs." Programs will support mentored research career development of junior faculty members, known as BIRCWH Scholars, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, behavioral, clinical, and/or health services research relevant to women's health, and where appropriate the use of both sexes to better understand the influence of sex as a variable on health and disease.

A letter of intent is due December 5 and applications are due January 5, 2015, by 5:00 PM local time of applicant organization.

For more information on this funding opportunity, visit the NIH website.

 
FOIA Requests

CWRU researchers who receive requests for information that invoke the Freedom of Information Act (FOIA) should contact the Office of General Counsel. This should be done immediately so the extremely short deadlines under FOIA can be met. General Counsel can work with the faculty member to take steps to protect proprietary or confidential information from grants and protocols prior to the release of the requested information. Individual researchers should not release information without first consulting with the CWRU Office of General Counsel.

For more information, contact the Office of General Counsel at: http://www.case.edu/president/counsel/contactus.html.

 

Case Comprehensive Cancer Center

All Faculty members are invited to submit concept proposals for 5 year Projects to compete for incorporation as a full project proposal in the upcoming GI SPORE competing renewal application that will be prepared starting in January 2015 for submission in September 2015 All proposals must be directed towards translational research of a GI malignancy, with at least one specific aim that involves direct study of patients or of human tissues.

Proposals must include two project leaders; one Basic Science leader and one Clinical leader. Maximum Funding Level – $185,000/year direct cost for 5 years ($925,000 total direct costs).

Completed proposals must be emailed to John Pounardjian, hxp125@case.edu. For more information on GI SPORE, visit the CaseCCC website.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.